HUP0000809A2 - Hosszan ható hatóanyagok és azokat tartalmazó gyógyszerkészítmények - Google Patents
Hosszan ható hatóanyagok és azokat tartalmazó gyógyszerkészítmények Download PDFInfo
- Publication number
- HUP0000809A2 HUP0000809A2 HU0000809A HUP0000809A HUP0000809A2 HU P0000809 A2 HUP0000809 A2 HU P0000809A2 HU 0000809 A HU0000809 A HU 0000809A HU P0000809 A HUP0000809 A HU P0000809A HU P0000809 A2 HUP0000809 A2 HU P0000809A2
- Authority
- HU
- Hungary
- Prior art keywords
- insulin
- fmoc
- group
- radical
- amino
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL11902996A IL119029A0 (en) | 1996-08-07 | 1996-08-07 | Long-acting drugs and pharamaceutical compositions comprising them |
| PCT/IL1997/000265 WO1998005361A2 (en) | 1996-08-07 | 1997-08-05 | Long-acting drugs and pharmaceutical compositions comprising them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUP0000809A2 true HUP0000809A2 (hu) | 2000-11-28 |
Family
ID=11069166
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0000809A HUP0000809A2 (hu) | 1996-08-07 | 1997-08-05 | Hosszan ható hatóanyagok és azokat tartalmazó gyógyszerkészítmények |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6504005B1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1019089B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4416184B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20000029806A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1227501A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE308998T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU725468B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR9711045A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2261835C (cg-RX-API-DMAC7.html) |
| CZ (1) | CZ36999A3 (cg-RX-API-DMAC7.html) |
| DE (1) | DE69734607T2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK1019089T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2252787T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUP0000809A2 (cg-RX-API-DMAC7.html) |
| IL (3) | IL119029A0 (cg-RX-API-DMAC7.html) |
| NO (1) | NO990518L (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ333845A (cg-RX-API-DMAC7.html) |
| WO (1) | WO1998005361A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL139400A0 (en) * | 2000-11-01 | 2001-11-25 | Yeda Res & Dev | Long-acting cytokine derivatives and pharmaceutical compositions comprising them |
| US7259233B2 (en) * | 2000-12-13 | 2007-08-21 | Eli Lilly And Company | Chronic treatment regimen using glucagon-like insulinotropic peptides |
| WO2003034988A2 (en) * | 2001-10-19 | 2003-05-01 | Idexx Laboratories, Inc. | Injectable compositions for the controlled delivery of pharmacologically active compound |
| US6946137B2 (en) * | 2001-10-19 | 2005-09-20 | Idexx Laboratories, Inc. | Methods for the controlled delivery of pharmacologically active compounds |
| US20030171285A1 (en) * | 2001-11-20 | 2003-09-11 | Finn Rory F. | Chemically-modified human growth hormone conjugates |
| BE1015608A6 (fr) * | 2003-07-15 | 2005-06-07 | Messadek Jallal | Traitement des arterites. |
| JP4033382B2 (ja) * | 2002-04-08 | 2008-01-16 | 久光製薬株式会社 | インスリン投与装置 |
| EP1583972B1 (en) * | 2003-01-16 | 2010-11-24 | caprotec bioanalytics GmbH | Methods for identifying drug non-target proteins |
| CA2521784C (en) | 2003-04-08 | 2012-03-27 | Yeda Research And Development Co. Ltd. | Reversible pegylated drugs |
| DE602004003577T2 (de) * | 2003-04-17 | 2007-09-20 | Jallal Messadek | Flottierende orale Formulierungen mit kontrollierter Freisetzung von Betain |
| BRPI0413276B8 (pt) | 2003-08-05 | 2021-05-25 | Novo Nordisk As | derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica |
| BE1016128A6 (fr) * | 2004-07-22 | 2006-03-07 | Messadek Jallal | Combinaisons therapeutiques |
| US7282487B2 (en) * | 2004-10-28 | 2007-10-16 | Idexx Laboratories | Method for treating bacterial infections in horses or pigs with tilmicosin |
| WO2006050581A2 (en) * | 2004-11-10 | 2006-05-18 | Jallal Messadek | Betaine as agent against arthropod - or mosquito -borne diseases |
| ATE540690T1 (de) * | 2005-04-27 | 2012-01-15 | Jallal Messadek | Insulinkombinationen |
| DK1969004T3 (da) | 2005-12-28 | 2011-11-28 | Novo Nordisk As | Insulinsammensætninger og metode til at lave en sammensætning |
| CN101677947B (zh) | 2007-06-13 | 2013-07-17 | 诺沃-诺迪斯克有限公司 | 包含胰岛素衍生物的药物制剂 |
| WO2009065193A1 (en) * | 2007-11-21 | 2009-05-28 | Jallal Messadek | Treatment of aspirin resistance with betaine and/or betaine enriched molasses |
| DK2910570T3 (en) | 2008-03-18 | 2017-01-30 | Novo Nordisk As | Protease-stabilized acylated insulin analogues. |
| EP2306986B1 (en) | 2008-06-26 | 2018-03-21 | Prolynx Llc | Prodrugs and drug-macromolecule conjugates having controlled drug release rates |
| WO2010033240A2 (en) | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Carbohydrate-based drug delivery polymers and conjugates thereof |
| US20110171312A1 (en) * | 2008-09-19 | 2011-07-14 | Nektar Therapeutics | Modified therapeutic peptides, methods of their preparation and use |
| EP2350658A2 (en) | 2008-10-21 | 2011-08-03 | Baxter International Inc. | Methods for determining active ingredients in pro-drug peg protein conjugates with releasable peg reagents (in vitro de-pegylation) |
| ES2607003T3 (es) * | 2008-10-30 | 2017-03-28 | Novo Nordisk A/S | Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyección inferior a la diaria |
| MX2011008963A (es) | 2009-03-05 | 2012-02-01 | Ascendis Pharma As | Profarmacos portadores de interferon alfa. |
| WO2011013128A2 (en) | 2009-07-31 | 2011-02-03 | Yeda Research And Development Co. Ltd. | Vectors for delivery of neurotherapeutics to the central nervous system |
| US8754190B2 (en) * | 2010-05-05 | 2014-06-17 | Prolynx Llc | Controlled release from macromolecular conjugates |
| JP6049625B2 (ja) | 2010-10-27 | 2016-12-21 | ノヴォ ノルディスク アー／エス | 様々な注射間隔を用いて施されるインスリン注射を使用する、真性糖尿病の治療 |
| EP2490378B1 (en) | 2011-02-18 | 2014-07-09 | NTT DoCoMo, Inc. | Apparatus and method for determining a control unit using feasibility requests and feasibility responses |
| EP2714070B1 (en) | 2011-06-02 | 2024-03-20 | OPKO Biologics Ltd. | Long-acting glp-1/glucagon receptor agonists |
| US10166295B2 (en) | 2011-06-02 | 2019-01-01 | Opko Biologics Ltd. | Pegylated OXM variants |
| US9481721B2 (en) | 2012-04-11 | 2016-11-01 | Novo Nordisk A/S | Insulin formulations |
| JP6290193B2 (ja) | 2012-06-04 | 2018-03-07 | オプコ バイオロジクス リミテッド | ペグ化ｏｘｍ変異体 |
| WO2014009316A1 (en) | 2012-07-09 | 2014-01-16 | Novo Nordisk A/S | Novel use of insulin derivatives |
| WO2014177623A1 (en) | 2013-04-30 | 2014-11-06 | Novo Nordisk A/S | Novel administration regime |
| TWI700091B (zh) | 2016-12-16 | 2020-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 含胰島素醫藥組成物 |
| US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
| US12441776B2 (en) | 2018-11-30 | 2025-10-14 | Eirgen Pharma Ltd. | Oxyntomodulin peptide analog formulations |
| CN113710692A (zh) | 2019-02-11 | 2021-11-26 | Opko生物科学有限公司 | 长效glp-2类似物 |
| WO2021009027A1 (en) | 2019-07-12 | 2021-01-21 | Novo Nordisk A/S | High concentration insulin formulation |
| CN113773398B (zh) * | 2020-06-10 | 2023-05-23 | 宁波鲲鹏生物科技有限公司 | 一种德谷胰岛素衍生物及其应用 |
| CN117551008B (zh) * | 2023-11-10 | 2025-10-17 | 沈阳药科大学 | 一种去铁胺偶联物及其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU906340D0 (en) * | 1986-10-13 | 1991-04-29 | Sandoz Ag | Synthesis in solid phase for producing peptonic alcohols |
| GB8717446D0 (en) | 1987-07-23 | 1987-08-26 | Merck Sharp & Dohme | Chemical compounds |
| US6313094B1 (en) * | 1990-12-11 | 2001-11-06 | Japan Energy Corporation | β-amino-α-hydroxycarboxylic acid derivatives and HIV protease inhibitors |
| JPH0687887A (ja) * | 1992-08-19 | 1994-03-29 | Upjohn Co:The | ペプチドのエナミン誘導体およびそれをプロドラッグとして含有するペプチド製剤 |
| WO1995000546A1 (en) | 1993-06-25 | 1995-01-05 | Kyowa Hakko Kogyo Co., Ltd. | Endothelin-antagonizing peptide |
| US5880131A (en) * | 1993-10-20 | 1999-03-09 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| WO1995021622A1 (en) | 1994-02-09 | 1995-08-17 | Brigham & Women's Hospital | Gel-forming polypeptide derivatives |
| DE4437604A1 (de) * | 1994-10-21 | 1996-04-25 | Basf Ag | Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung |
| WO1996030267A2 (en) * | 1995-03-30 | 1996-10-03 | Southpac Trust International, Inc. | Self-erecting container which is collapsible to be substantially flat |
| US5688992A (en) * | 1995-03-31 | 1997-11-18 | The United States Of America As Represented By The Department Of Health And Human Services | O-malonyltryrosyl compounds, O-malonyltryrosyl compound-containing peptides, and use thereof |
| US5846934A (en) * | 1996-02-20 | 1998-12-08 | American Cyanamid Company | Pure somatostatin antagonist and methods of use thereof |
| US6057297A (en) * | 1996-08-06 | 2000-05-02 | Polifarma S.P.A. | Inhibitor compounds of zinc-dependent metalloproteinases associated with pathological conditions, and therapeutic use thereof |
-
1996
- 1996-08-07 IL IL11902996A patent/IL119029A0/xx unknown
-
1997
- 1997-08-05 CZ CZ99369A patent/CZ36999A3/cs unknown
- 1997-08-05 HU HU0000809A patent/HUP0000809A2/hu unknown
- 1997-08-05 WO PCT/IL1997/000265 patent/WO1998005361A2/en not_active Ceased
- 1997-08-05 EP EP97933828A patent/EP1019089B1/en not_active Expired - Lifetime
- 1997-08-05 DK DK97933828T patent/DK1019089T3/da active
- 1997-08-05 KR KR1019997000941A patent/KR20000029806A/ko not_active Withdrawn
- 1997-08-05 AU AU37060/97A patent/AU725468B2/en not_active Ceased
- 1997-08-05 ES ES97933828T patent/ES2252787T3/es not_active Expired - Lifetime
- 1997-08-05 IL IL12827497A patent/IL128274A0/xx active IP Right Grant
- 1997-08-05 NZ NZ333845A patent/NZ333845A/xx unknown
- 1997-08-05 JP JP50777098A patent/JP4416184B2/ja not_active Expired - Lifetime
- 1997-08-05 CN CN97197122A patent/CN1227501A/zh active Pending
- 1997-08-05 BR BR9711045A patent/BR9711045A/pt not_active IP Right Cessation
- 1997-08-05 AT AT97933828T patent/ATE308998T1/de active
- 1997-08-05 CA CA002261835A patent/CA2261835C/en not_active Expired - Lifetime
- 1997-08-05 US US09/242,026 patent/US6504005B1/en not_active Expired - Lifetime
- 1997-08-05 DE DE69734607T patent/DE69734607T2/de not_active Expired - Lifetime
-
1999
- 1999-01-28 IL IL128274A patent/IL128274A/en not_active IP Right Cessation
- 1999-02-04 NO NO990518A patent/NO990518L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2261835C (en) | 2008-07-29 |
| ES2252787T3 (es) | 2006-05-16 |
| AU725468B2 (en) | 2000-10-12 |
| EP1019089A2 (en) | 2000-07-19 |
| ATE308998T1 (de) | 2005-11-15 |
| JP2000515542A (ja) | 2000-11-21 |
| IL119029A0 (en) | 1996-11-14 |
| WO1998005361A3 (en) | 1998-06-18 |
| IL128274A0 (en) | 1999-11-30 |
| CN1227501A (zh) | 1999-09-01 |
| JP4416184B2 (ja) | 2010-02-17 |
| US6504005B1 (en) | 2003-01-07 |
| NO990518D0 (no) | 1999-02-04 |
| EP1019089B1 (en) | 2005-11-09 |
| DE69734607D1 (de) | 2005-12-15 |
| CA2261835A1 (en) | 1998-02-12 |
| IL128274A (en) | 2006-08-01 |
| DK1019089T3 (da) | 2006-03-13 |
| CZ36999A3 (cs) | 1999-07-14 |
| NZ333845A (en) | 2000-09-29 |
| DE69734607T2 (de) | 2006-08-03 |
| NO990518L (no) | 1999-04-06 |
| KR20000029806A (ko) | 2000-05-25 |
| AU3706097A (en) | 1998-02-25 |
| WO1998005361A2 (en) | 1998-02-12 |
| BR9711045A (pt) | 1999-08-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0000809A2 (hu) | Hosszan ható hatóanyagok és azokat tartalmazó gyógyszerkészítmények | |
| ES2542146T3 (es) | Insulinas extendidas PEGiladas. | |
| EP1969004B1 (en) | Compositions comprising an acylated insulin and zinc and method of making the said compositions | |
| JP5220410B2 (ja) | インスリン−オリゴマー複合体、その処方物及び使用 | |
| EP1478233B1 (en) | Method for administering glp-1 molecules | |
| EP2107069B1 (en) | Novel insulin derivatives | |
| US8722620B2 (en) | Insulin derivatives | |
| ES2548304T3 (es) | Análogos de la insulina que contienen una fracción acilo y alquilenglicol | |
| EP2437786B1 (en) | Prodrugs containing albumin binding probe | |
| CN110022902A (zh) | 包含glp-1/胰高血糖素双重激动剂、接头和透明质酸的缀合物 | |
| WO2002008250A2 (en) | Ghrelin antagonists | |
| JP2000060556A (ja) | アシル化インスリン | |
| JP2008504249A (ja) | 糖尿病を治療するための方法 | |
| KR20090043510A (ko) | 펩타이드의 지속 방출 전달을 위한 약학적 조성물 | |
| HUP0004096A2 (hu) | A humán inzulinszármazékok aggregátumai és ezeket tartalmazó gyógyszerészeti készítmény | |
| CN116419750A (zh) | 改进的glp-1受体激动剂的药物制剂 | |
| US20030162721A1 (en) | Pharmaceutical composition containing peptichemio | |
| CN119454605B (zh) | 一种实现多肽口服吸收的组合物 | |
| US6740639B1 (en) | Inclusion complees of a high potent opioid peptide, pharmaceutical compositions and method of treatment | |
| JPS6094999A (ja) | インシユリン誘導体およびその製法 | |
| Gershonov | Novel strategy for preparation of long-acting drugs: Studies on insulin | |
| WO2019037393A1 (zh) | 一种对glp-1受体具有高亲和性的多肽化合物及其制备方法和应用 | |
| CN1964989B (zh) | 长效胰岛素衍生物及其方法 |